The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC).
 
Melissa Lynne Johnson
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma (I); Otsuka (I)
Research Funding - Novartis
 
Alex A. Adjei
No Relationships to Disclose
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Pasi A. Janne
No Relationships to Disclose
 
George Dominguez
Consulting or Advisory Role - Syndax
 
Dmitry Gabrilovich
Consulting or Advisory Role - Syndax
 
Laura Deleon
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Jeannette Lynne Hasapidis
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Peter Ordentlich
Employment - Syndax
Stock and Other Ownership Interests - Syndax
 
Matthew David Hellmann
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Inovio Pharmaceuticals; Merck; Third Rock Ventures
Research Funding - Bristol-Myers Squibb